急性缺血性卒中伴大血管闭塞(acute ischemic stroke with large vessel occlusion,AIS-LVO)是鼻咽癌患者的少见并发症,且治疗难度较大。本文报道了2例鼻咽癌相关性AIS-LVO患者,其中1例为鼻咽癌放疗后出现颈内动脉假性动脉瘤合并出血患...急性缺血性卒中伴大血管闭塞(acute ischemic stroke with large vessel occlusion,AIS-LVO)是鼻咽癌患者的少见并发症,且治疗难度较大。本文报道了2例鼻咽癌相关性AIS-LVO患者,其中1例为鼻咽癌放疗后出现颈内动脉假性动脉瘤合并出血患者,覆膜支架置入术后出现急性支架内血栓闭塞,经血管内治疗后颈内动脉复通;另1例为鼻咽癌放疗后出现颈内动脉闭塞患者,经血管内治疗后颈内动脉复通。本文对这2例鼻咽癌相关性AI S-LVO患者的诊治过程进行分析和讨论,以期为临床治疗鼻咽癌合并脑动脉闭塞提供借鉴。展开更多
卒中后抑郁是一种常见的卒中并发症,对患者的康复和生活质量有着显著影响。约三分一卒中患者伴有糖尿病,而糖尿病可加剧卒中后抑郁的风险,两者之间在病理生理学上存在相互促进的关系。本文将探讨糖尿病与卒中后抑郁之间的病理生理学联系...卒中后抑郁是一种常见的卒中并发症,对患者的康复和生活质量有着显著影响。约三分一卒中患者伴有糖尿病,而糖尿病可加剧卒中后抑郁的风险,两者之间在病理生理学上存在相互促进的关系。本文将探讨糖尿病与卒中后抑郁之间的病理生理学联系,并从药物治疗的角度进行分析,旨在为合并糖尿病的卒中后抑郁患者提供预防和诊治参考。Post-stroke depression is a common complication of stroke, significantly affecting patients’ recovery and quality of life. Approximately one-third of stroke patients are diagnosed with diabetes, and diabetes can exacerbate the risk of post-stroke depression. There is a mutually reinforcing relationship between the two in terms of pathophysiology. This article will explore the pathophysiological connection between diabetes and post-stroke depression and analyze it from the perspective of drug therapy, aiming to provide prevention and treatment references for patients with post-stroke depression who also have diabetes.展开更多
在缺血性卒中的多种风险原因中,高脂血症特别是高胆固醇血症始终占有着很关键的地位,通过降低血浆中胆固醇特别是低密度脂蛋白胆固醇的水平,可以很有效地减少缺血性卒中发生的风险,这一观点已是世界神经科专家的普遍共识。他汀类药物是...在缺血性卒中的多种风险原因中,高脂血症特别是高胆固醇血症始终占有着很关键的地位,通过降低血浆中胆固醇特别是低密度脂蛋白胆固醇的水平,可以很有效地减少缺血性卒中发生的风险,这一观点已是世界神经科专家的普遍共识。他汀类药物是缺血性卒中二级预防的基石,被广泛应用于临床,然而,他汀类药物也有其自身的局限性。首先,如果他汀类药物剂量增加一倍,其降脂效果仅增加6%,这使得许多患者仅靠他汀类药物很难达到LDL-C目标。其次,有些患者不能耐受他汀类药物,这一现象在接受大剂量他汀类药物治疗的中国患者中尤为明显。近几年新上市的新型降脂药物–前蛋白转化酶枯草溶菌素9 (proprotein convertase subtilisin/kexin type 9, PCSK9)抑制剂则为缺血性卒中的治疗提供了新的策略。Among the myriad risk factors for ischemic stroke, hyperlipidemia, particularly hypercholesterolemia, consistently holds a pivotal role. The reduction of plasma cholesterol levels, notably low-density lipoprotein cholesterol (LDL-C), has been recognized as an effective strategy to mitigate the risk of ischemic stroke. This perspective has garnered widespread acceptance among neurology experts globally. Statins, as the mainstay of secondary prevention for ischemic stroke, are extensively utilized in clinical settings. However, statins are not without their inherent limitations. Firstly, the lipid-lowering efficacy of statins plateaus with increased dosage;doubling the dose results in a mere 6% increase in cholesterol reduction, making it challenging for many patients to achieve their LDL-C targets with statin monotherapy. Secondly, statin intolerance is not uncommon, with a pronounced incidence observed among Chinese patients undergoing high-dose statin therapy. In this context, the advent of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of lipid-lowering agents, offers a promising alternative for the management of ischemic stroke, presenting a new therapeutic horizon in the field.展开更多
血脑屏障(blood brain barrier, BBB)是存在于外周血液和脑组织之间的结构,保护大脑免受内源性及外源性毒素和病原体的侵害,从而维持脑内环境稳定。在中枢神经系统疾病中,血脑屏障的破坏将进一步加剧疾病的进展。研究表明血小板源性生...血脑屏障(blood brain barrier, BBB)是存在于外周血液和脑组织之间的结构,保护大脑免受内源性及外源性毒素和病原体的侵害,从而维持脑内环境稳定。在中枢神经系统疾病中,血脑屏障的破坏将进一步加剧疾病的进展。研究表明血小板源性生长因子(platelet-derived growth factor, PDGF)在血脑屏障的形成及功能维持中发挥重要作用,本文总结了PDGF及其受体在生理及病理情况下对血脑屏障的影响,初步探讨PDGF在中枢神经系统疾病中的治疗可能性,并对当前靶向PDGF及其受体的治疗手段进行简要综述。The blood brain barrier (BBB) is a structure that exists between peripheral blood and brain tissue, protecting the brain from endogenous and exogenous toxins and pathogens, thereby maintaining the stability of the brain internal environment. In central nervous system diseases, the disruption of BBB further exacerbates disease progression. Compelling data indicates that platelet-derived growth factor (PDGF) plays an important role in the maintenance and formation of BBB. This article summarizes the effects of PDGFs and their receptors on the integrity of BBB under physiological and pathological conditions. Finally, we briefly summarize the potential therapeutic strategy of PDGFs in central nervous system diseases, and review the current therapeutic methods targeting PDGFR.展开更多
多灶性运动神经病(multifocal motor neuropathy,MMN)是一种罕见的获得性运动神经病,其发病机制可能与抗GM1抗体相关,多种下运动神经元疾病易与之混淆。肩关节撞击综合征又称肩峰下撞击综合征,通常是由于某种原因导致肩峰与肱骨头之间...多灶性运动神经病(multifocal motor neuropathy,MMN)是一种罕见的获得性运动神经病,其发病机制可能与抗GM1抗体相关,多种下运动神经元疾病易与之混淆。肩关节撞击综合征又称肩峰下撞击综合征,通常是由于某种原因导致肩峰与肱骨头之间等软组织结构遭受到不同程度的磨损挤压后引发病理性的损伤。当多灶性运动神经病合并肩关节病变时,症状的相似掺杂增加了此病确诊的难度。展开更多
文摘目的应用磁共振弥散张量成像(diffusion tensorimaging,DTI)技术前瞻性动态观察皮质下或脑干局灶性脑梗死后,病灶上方继发的神经纤维逆行性变性的过程,探讨其对神经功能恢复的影响。方法选择具有单侧内囊区或脑干的独立病灶的脑梗死患者16例,选择年龄及性别相匹配的健康志愿者16名作为对照组。患者分别在发病的第1周(W1)、第4周(W4)、第12周(W12)进行DTI检测和美国国立卫生研究院卒中评分(national institutes of health stroke scale,NIHSS)、简式Fugl-Meyer运动功能评分法(FM)和Barthel生活指数(Barthel Index,BI)评分。计算半卵园中心的DTI参数和各临床评分在观察期内变化的百分数绝对值,分析两者之间的相关关系。结果与对照组比较,病灶上方半卵园中心的部分弥散各向异性(fractional anisotropy,FA)值在各个时间点均明显减少(患者组W1:(0.43±0.02),W4:(0.39±0.01),W12:(0.33±0.02),分别与对照组比较:(0.46±0.01),P<0.01),而平均弥散量(mean diffusivity,MD)无统计学差异(P>0.05)。患者从W1至W12,半卵园中心FA值减少的百分数的绝对值与NIHSS评分减少百分数的绝对值之间(r=-0.49,P<0.05)及与FM增加百分数的绝对值之间(r=-0.56,P<0.05)呈负相关,与BI变化的百分数的绝对值之间无明显相关(P>0.05)。结论局灶性皮质下脑梗死可引起神经纤维逆行性的继发性变性,而且这种逆行性的神经纤维继发性变性会持续存在并可能阻碍患者神经功能的恢复。
文摘急性缺血性卒中伴大血管闭塞(acute ischemic stroke with large vessel occlusion,AIS-LVO)是鼻咽癌患者的少见并发症,且治疗难度较大。本文报道了2例鼻咽癌相关性AIS-LVO患者,其中1例为鼻咽癌放疗后出现颈内动脉假性动脉瘤合并出血患者,覆膜支架置入术后出现急性支架内血栓闭塞,经血管内治疗后颈内动脉复通;另1例为鼻咽癌放疗后出现颈内动脉闭塞患者,经血管内治疗后颈内动脉复通。本文对这2例鼻咽癌相关性AI S-LVO患者的诊治过程进行分析和讨论,以期为临床治疗鼻咽癌合并脑动脉闭塞提供借鉴。
文摘卒中后抑郁是一种常见的卒中并发症,对患者的康复和生活质量有着显著影响。约三分一卒中患者伴有糖尿病,而糖尿病可加剧卒中后抑郁的风险,两者之间在病理生理学上存在相互促进的关系。本文将探讨糖尿病与卒中后抑郁之间的病理生理学联系,并从药物治疗的角度进行分析,旨在为合并糖尿病的卒中后抑郁患者提供预防和诊治参考。Post-stroke depression is a common complication of stroke, significantly affecting patients’ recovery and quality of life. Approximately one-third of stroke patients are diagnosed with diabetes, and diabetes can exacerbate the risk of post-stroke depression. There is a mutually reinforcing relationship between the two in terms of pathophysiology. This article will explore the pathophysiological connection between diabetes and post-stroke depression and analyze it from the perspective of drug therapy, aiming to provide prevention and treatment references for patients with post-stroke depression who also have diabetes.
文摘在缺血性卒中的多种风险原因中,高脂血症特别是高胆固醇血症始终占有着很关键的地位,通过降低血浆中胆固醇特别是低密度脂蛋白胆固醇的水平,可以很有效地减少缺血性卒中发生的风险,这一观点已是世界神经科专家的普遍共识。他汀类药物是缺血性卒中二级预防的基石,被广泛应用于临床,然而,他汀类药物也有其自身的局限性。首先,如果他汀类药物剂量增加一倍,其降脂效果仅增加6%,这使得许多患者仅靠他汀类药物很难达到LDL-C目标。其次,有些患者不能耐受他汀类药物,这一现象在接受大剂量他汀类药物治疗的中国患者中尤为明显。近几年新上市的新型降脂药物–前蛋白转化酶枯草溶菌素9 (proprotein convertase subtilisin/kexin type 9, PCSK9)抑制剂则为缺血性卒中的治疗提供了新的策略。Among the myriad risk factors for ischemic stroke, hyperlipidemia, particularly hypercholesterolemia, consistently holds a pivotal role. The reduction of plasma cholesterol levels, notably low-density lipoprotein cholesterol (LDL-C), has been recognized as an effective strategy to mitigate the risk of ischemic stroke. This perspective has garnered widespread acceptance among neurology experts globally. Statins, as the mainstay of secondary prevention for ischemic stroke, are extensively utilized in clinical settings. However, statins are not without their inherent limitations. Firstly, the lipid-lowering efficacy of statins plateaus with increased dosage;doubling the dose results in a mere 6% increase in cholesterol reduction, making it challenging for many patients to achieve their LDL-C targets with statin monotherapy. Secondly, statin intolerance is not uncommon, with a pronounced incidence observed among Chinese patients undergoing high-dose statin therapy. In this context, the advent of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of lipid-lowering agents, offers a promising alternative for the management of ischemic stroke, presenting a new therapeutic horizon in the field.
文摘血脑屏障(blood brain barrier, BBB)是存在于外周血液和脑组织之间的结构,保护大脑免受内源性及外源性毒素和病原体的侵害,从而维持脑内环境稳定。在中枢神经系统疾病中,血脑屏障的破坏将进一步加剧疾病的进展。研究表明血小板源性生长因子(platelet-derived growth factor, PDGF)在血脑屏障的形成及功能维持中发挥重要作用,本文总结了PDGF及其受体在生理及病理情况下对血脑屏障的影响,初步探讨PDGF在中枢神经系统疾病中的治疗可能性,并对当前靶向PDGF及其受体的治疗手段进行简要综述。The blood brain barrier (BBB) is a structure that exists between peripheral blood and brain tissue, protecting the brain from endogenous and exogenous toxins and pathogens, thereby maintaining the stability of the brain internal environment. In central nervous system diseases, the disruption of BBB further exacerbates disease progression. Compelling data indicates that platelet-derived growth factor (PDGF) plays an important role in the maintenance and formation of BBB. This article summarizes the effects of PDGFs and their receptors on the integrity of BBB under physiological and pathological conditions. Finally, we briefly summarize the potential therapeutic strategy of PDGFs in central nervous system diseases, and review the current therapeutic methods targeting PDGFR.
文摘多灶性运动神经病(multifocal motor neuropathy,MMN)是一种罕见的获得性运动神经病,其发病机制可能与抗GM1抗体相关,多种下运动神经元疾病易与之混淆。肩关节撞击综合征又称肩峰下撞击综合征,通常是由于某种原因导致肩峰与肱骨头之间等软组织结构遭受到不同程度的磨损挤压后引发病理性的损伤。当多灶性运动神经病合并肩关节病变时,症状的相似掺杂增加了此病确诊的难度。
